2024
Chimeric antigen receptors: “CARs” in the fast lane for rheumatology
Johnson N, Koumpouras F. Chimeric antigen receptors: “CARs” in the fast lane for rheumatology. Current Opinion In Rheumatology 2024, 36: 176-183. PMID: 38517338, PMCID: PMC11224568, DOI: 10.1097/bor.0000000000001012.Peer-Reviewed Original ResearchConceptsChimeric antigen receptorCAR-T treatmentCAR-TB cellsAutoimmune diseasesRheumatologic diseasesReview current clinical dataSevere refractory autoimmune diseasesReconstitution of B cellsRefractory autoimmune diseasesTreatment of rheumatologic diseasesB-cell malignanciesCompassionate use programB cell populationsLaboratory remissionRefractory SLECD19-CARField of autoimmunityRefractory diseaseClinical responseNaive phenotypeSevere lupusMultiple myelomaAutoimmune modelsT cells
2023
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial
Merrill J, Guthridge J, Smith M, June J, Koumpouras F, Machua W, Askanase A, Khosroshahi A, Sheikh S, Rathi G, Burington B, Foster P, Matijevic M, Arora S, Wang X, Gao M, Wax S, James J, Zack D. Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co‐Expression Patterns: A Double‐Blind, Randomized, Placebo‐Controlled, Phase 2 Trial. Arthritis & Rheumatology 2023, 75: 2185-2194. PMID: 37459248, DOI: 10.1002/art.42652.Peer-Reviewed Original ResearchConceptsSystemic lupus erythematosusLoss of improvementPrimary endpointLupus erythematosusWeek 32B cellsEfficacy-evaluable populationImproved disease activityPhase 2 trialProportion of patientsTreatment-related toxicityTreatment of patientsPlacebo-ControlledCorticosteroid injectionDisease activityInfusion reactionsTrough concentrationsPatient subsetsPlasma cellsPatientsSecondary analysisMonoclonal antibodiesStatistical significanceEndpointPlacebo